Back to Archived News
EnWave Files bioREV Equipment and Methodology Patent for Vaccine Dehydration
Friday, September 14, 2007
Vancouver, British Columbia -- EnWave Corporation (TSX VENTURE: ENW) (FRANKFURT:E4U) ("EnWave" or "the Company") wishes to report that Dr. Tim Durance and EnWave Senior Engineer Leon Fu have filed a US patent application on behalf of EnWave to protect the Company's proprietary equipment and processes for dehydration of vaccines and similar pharmaceutical materials. EnWave has previously licensed worldwide commercial rights to eight other patented technologies from the University of British Columbia. If the present patent application is successful, it will represent the first patent owned outright by the Company.
This patent application, which the Company expects to be evaluated by US patent examiners within the next eighteen months, represents further intellectual property development of the Company's bioREV technology. This prototype equipment is currently being tested in a newly established Company laboratory. Once initial testing is completed, the unit will be transferred to EnWave's collaboration partner, Aridis Pharmaceuticals, LLC, in San Jose, California, where it will be used to test the effectiveness of bioREV in producing room temperature stable vaccines and antibodies. The goal of the project is to determine whether bioREV processed products can be produced faster, with fewer organism or batch losses, at a cheaper cost, and with longer shelf-life than those produced using the conventional method of freeze-drying.
Dr. Tim Durance, Chairman and Co-CEO of EnWave, stated that "EnWave is continuing to protect its intellectual property in a vigorous manner to ensure that the strength of our discoveries can be used to their full potential by our research partners. I am excited by this latest filing as it means that we can now demonstrate bioREV to a wider group of companies who may be interested in new methods of dehydration for sensitive biological materials. The new equipment will allow us and our partners to quickly dehydrate vaccines directly in the containers typically used by this industry."
Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating biological materials using Radiant Energy Vacuum technology, under its bioREV brand. bioREV technology combines microwave energy transfer with pressure control to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for medical applications that include dry vaccines, bone and tissue engineering, and drug delivery. More information about EnWave is available at www.enwave.net.
Safe Harbour for Forward-Looking Information Statements
This release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Forward looking statements in this press release include: "may offer commercial potential" and "expected to begin". These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's bioREV technology can or will be used to develop materials for the tissue engineering or drug delivery markets; even if the Company's bioREV technology can be used as described in this news release, there is no guarantee that such use will result in orders for the Company's bioREV technology. There is no guarantee that the patent subject of this press release will be granted.
Back to Archived News